310 related articles for article (PubMed ID: 23936497)
1. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Dultz G; Seelhof M; Herrmann E; Welker MW; Friedrich-Rust M; Teuber G; Kronenberger B; von Wagner M; Vermehren J; Sarrazin C; Zeuzem S; Hofmann WP
PLoS One; 2013; 8(8):e71262. PubMed ID: 23936497
[TBL] [Abstract][Full Text] [Related]
2. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
4. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Zangneh HF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
J Hepatol; 2014 Sep; 61(3):482-91. PubMed ID: 24780302
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
Labarga P; Fernández-Montero JV; de Mendoza C; Barreiro P; Soriano V
Antivir Ther; 2015; 20(1):65-72. PubMed ID: 25105286
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
8. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C.
Martínez-Macías RF; Cordero-Pérez P; Juárez-Rodríguez OA; Chen-López CY; Martínez-Carrillo FM; Alarcón-Galván G; Mercado-Hernández R; Muñoz-Espinosa LE
Ann Hepatol; 2015; 14(1):36-45. PubMed ID: 25536640
[TBL] [Abstract][Full Text] [Related]
9. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
11. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
[TBL] [Abstract][Full Text] [Related]
12. Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia.
Hofer H; Gurguta C; Bergholz U; Steindl-Munda P; Ferenci P
Wien Klin Wochenschr; 2006 Oct; 118(19-20):595-600. PubMed ID: 17136334
[TBL] [Abstract][Full Text] [Related]
13. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.
Iacobellis A; Andriulli A
Expert Opin Pharmacother; 2009 Aug; 10(12):1929-38. PubMed ID: 19563272
[TBL] [Abstract][Full Text] [Related]
14. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
15. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
Welker MW; Luhne S; Lange CM; Vermehren J; Farnik H; Herrmann E; Welzel T; Zeuzem S; Sarrazin C
J Hepatol; 2016 Apr; 64(4):790-9. PubMed ID: 26658684
[TBL] [Abstract][Full Text] [Related]
16. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
Kim KH; Jang BK; Chung WJ; Hwang JS; Kweon YO; Tak WY; Lee HJ; Lee CH; Suh JI
Korean J Hepatol; 2011 Sep; 17(3):220-5. PubMed ID: 22102389
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir for previously untreated chronic hepatitis C infection.
Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
[TBL] [Abstract][Full Text] [Related]
19. [A clinical study of antiviral therapy for patients with compensated hepatitis C cirrhosis].
Xie ZW; Li JP; Guan YJ; Zhang XY; Guo FX; Chen BB; Pan CQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):827-833. PubMed ID: 29325276
[No Abstract] [Full Text] [Related]
20. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
Mak SK; Sin HK; Lo KY; Lo MW; Chan SF; Lo KC; Wong YY; Ho LY; Wong PN; Wong AKM
Clin Exp Nephrol; 2017 Oct; 21(5):764-770. PubMed ID: 28083764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
